Cargando…
P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171789/ http://dx.doi.org/10.1097/01.HS9.0000936184.12325.62 |
| _version_ | 1785039497895870464 |
|---|---|
| author | Ntanasis-Stathopoulos, I. Gavriatopoulou, M. Malandrakis, P. Fotiou, D. Kanellias, N. Migkou, M. Theodorakakou, F. Spiliopoulou, V. Syrigou, R. Eleutherakis-Papaiakovou, E. Gkolfinopoulos, S. Manousou, K. Kastritis, E. Dimopoulos, M.A. Terpos, E. |
| author_facet | Ntanasis-Stathopoulos, I. Gavriatopoulou, M. Malandrakis, P. Fotiou, D. Kanellias, N. Migkou, M. Theodorakakou, F. Spiliopoulou, V. Syrigou, R. Eleutherakis-Papaiakovou, E. Gkolfinopoulos, S. Manousou, K. Kastritis, E. Dimopoulos, M.A. Terpos, E. |
| author_sort | Ntanasis-Stathopoulos, I. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171789 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101717892023-05-11 P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL Ntanasis-Stathopoulos, I. Gavriatopoulou, M. Malandrakis, P. Fotiou, D. Kanellias, N. Migkou, M. Theodorakakou, F. Spiliopoulou, V. Syrigou, R. Eleutherakis-Papaiakovou, E. Gkolfinopoulos, S. Manousou, K. Kastritis, E. Dimopoulos, M.A. Terpos, E. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171789/ http://dx.doi.org/10.1097/01.HS9.0000936184.12325.62 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Ntanasis-Stathopoulos, I. Gavriatopoulou, M. Malandrakis, P. Fotiou, D. Kanellias, N. Migkou, M. Theodorakakou, F. Spiliopoulou, V. Syrigou, R. Eleutherakis-Papaiakovou, E. Gkolfinopoulos, S. Manousou, K. Kastritis, E. Dimopoulos, M.A. Terpos, E. P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title | P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_full | P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_fullStr | P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_full_unstemmed | P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_short | P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_sort | p14 ocular toxicity in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin, lenalidomide and dexamethasone in a phase 1/2 trial |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171789/ http://dx.doi.org/10.1097/01.HS9.0000936184.12325.62 |
| work_keys_str_mv | AT ntanasisstathopoulosi p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT gavriatopouloum p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT malandrakisp p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT fotioud p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT kanelliasn p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT migkoum p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT theodorakakouf p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT spiliopoulouv p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT syrigour p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT eleutherakispapaiakovoue p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT gkolfinopouloss p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT manousouk p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT kastritise p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT dimopoulosma p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT terpose p14oculartoxicityintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial |